News

Papers don’t tell the whole story
Enlarge image

PolicyGermanyEU

Papers don’t tell the whole story

09.10.2013 - According to a new study, clinical trial outcomes are more complete in unpublished reports than in publicly available information.

Publicly available sources of information that report findings from clinical trials provide much less information on patient-relevant outcomes than unpublished reports, states a study published by German researchers. The results of the study by Beate Wieseler and colleagues from the Institute for Quality and Efficiency in Health Care (IQWIG) in Cologne found that the publicly available information contained less information about both the benefits and potential harms of an intervention than the unpublished report. Their findings highlight the importance of recent initiatives, such as the AllTrials initiative that aims to make clinical trial outcome data publicly available, in order to provide complete and transparent information to help patients and clinicians reach decisions about clinical care.

In the study, the researchers compared the information available in clinical study reports, which are detailed but usually unpublished accounts of clinical trials, to publicly available sources, including journal publications and registry reports. They found that unpublished reports included complete information for 86% of the patient-relevant outcomes, whereas the combined publicly available sources provided complete information for only 39% of the outcomes. Although the trials included in this study may not be representative of all trials, the findings support a draft policy released in June 2013 by the European Medicines Agency calling for the routine publication of complete clinical trial data.

The authors say: "Our findings show that a substantial amount of information on patient-relevant outcomes required for unbiased trial evaluation is missing from the public record. [Clinical study reports] should be made publicly available as they may substantially influence conclusions concerning the actual position of an individual drug in a therapeutic area."

The study is just another piece in the ongoing debate on transparency of clinical trials set to be implemented in the new EU clinical trials regulation. The pharma industry has stated its will to share clinical data of approved drugs but has also pointed out that it would be essential to exclude any use or misuse of personal data, i.e. when it comes to trials on orphan drugs. In May, the General Court of the European Union ordered the EMA not to provide any raw data on pivotal clinical trials of EU-approved drugs to competitors of originator drugs' developers.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-04/papers-dont-tell-the-whole-story.html

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%
  • ADDEX3.30 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.97 EUR0.00%
  • ACTELION112.40 CHF0.00%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 25.10.2014